DeepMed Research

Midomafetamine

Generic Name: Midomafetamine

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₅NO_₂

CAS Number: 42542-10-9

Unique Ingredient Identifier: KE1SEN21RM

Background: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

Indication: Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.

Clinical Trials

Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: Psilocybin
Drug: 3,4-Methylenedioxymethamphetamine
Drug: 3,4-Methylenedioxymethamphetamine placebo
Drug: Psilocybin placebo

First Posted Date: 2025-03-19

Last Posted Date: 2025-05-21

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 24

Registration Number: NCT06884514

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls

Not Applicable

Recruiting

Conditions: Central Diabetes Insipidus

Interventions: Drug: MDMA
Other: Placebo

First Posted Date: 2025-01-23

Last Posted Date: 2025-02-19

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 24

Registration Number: NCT06789705

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder

Phase 2

Recruiting

Conditions: Social Anxiety Disorder

Interventions: Drug: EMP-01 Placebo
Drug: EMP-01

First Posted Date: 2024-11-18

Last Posted Date: 2025-05-13

Lead Sponsor: atai Therapeutics, Inc.

Target Recruit Count: 60

Registration Number: NCT06693609

Locations: 🇬🇧
MAC Clinical Research - South Staffordshire, Bridgetown, Cannock, Staffordshire, United Kingdom
🇬🇧
MAC Clinical Research - Greater Manchester, Manchester, Greater Manchester, United Kingdom
🇬🇧
MAC Clinical Research - Lancashire, Blackpool, Lancashire, United Kingdom

and more 3 locations

MDMA in Borderline Personality Disorder

Phase 2

Not yet recruiting

Conditions: Borderline Personality Disorder

Interventions: Drug: MDMA

First Posted Date: 2024-11-12

Last Posted Date: 2025-04-29

Lead Sponsor: Yale University

Target Recruit Count: 10

Registration Number: NCT06683014

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

MDMA-Assisted Therapy for Pathological Narcissism

Early Phase 1

Recruiting

Conditions: Narcissism

Interventions: Drug: midomafetamine (MDMA)-Assisted Therapy

First Posted Date: 2024-08-22

Last Posted Date: 2024-08-28

Lead Sponsor: University of Washington

Target Recruit Count: 12

Registration Number: NCT06565494

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Dose Optimization of MDMA-Assisted Therapy for PTSD

Phase 2

Not yet recruiting

Conditions: Posttraumatic Stress Disorder

Interventions: Drug: Midomafetamine
Behavioral: Psychotherapy

First Posted Date: 2024-05-17

Last Posted Date: 2024-05-17

Lead Sponsor: Bronx VA Medical Center

Target Recruit Count: 60

Registration Number: NCT06418178

MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents

Phase 2

Withdrawn

Conditions: PTSD, Post Traumatic Stress Disorder
Adolescents
Psychotherapy

Interventions: Drug: MDMA
Behavioral: Psychotherapy

First Posted Date: 2024-04-09

Last Posted Date: 2025-04-10

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 10

Registration Number: NCT06353282

Locations: 🇺🇸
UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States

Epigenetics and MDMA-Assisted Psychotherapy for PTSD

Phase 3

Active, not recruiting

Conditions: PTSD

Interventions: Drug: MDMA
Behavioral: Psychotherapy

First Posted Date: 2024-01-03

Last Posted Date: 2024-01-03

Lead Sponsor: University of Southern California

Target Recruit Count: 45

Registration Number: NCT06189027

Locations: 🇺🇸
Univeristy of Southern California, Los Angeles, California, United States

MDMA-assisted Massed Prolonged Exposure for PTSD

Phase 3

Recruiting

Conditions: Post-Traumatic Stress Disorder

Interventions: Drug: 3,4 Methylenedioxymethamphetamine
Behavioral: Prolonged Exposure

First Posted Date: 2023-11-07

Last Posted Date: 2025-03-26

Lead Sponsor: Healing Breakthrough

Target Recruit Count: 10

Registration Number: NCT06117306

Locations: 🇺🇸
VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States

Does Serotonin System Stimulation Increase Pro-social Behavior? - a Comparative Pharmacological Neuroscientific Study in Healthy Humans

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: Psilocybin
Drug: 3,4 Methylenedioxymethamphetamine
Drug: Methylphenidate

First Posted Date: 2023-10-13

Last Posted Date: 2025-03-26

Lead Sponsor: University of Zurich

Target Recruit Count: 120

Registration Number: NCT06081179

Locations: 🇨🇭
Psychiatrische Universitätsklinik Zürich, Zürich, Switzerland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy